Plain-English translation of NCT06819215 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer medication called in people with advanced solid tumors (cancers that have spread). The medication works by targeting specific genetic changes in cancer cells that make them vulnerable to treatment. Researchers want to learn whether the medication is safe and whether it can help slow or shrink these cancers.
Standard cancer treatments don't work for everyone, especially patients whose tumors have specific genetic mutations. This trial explores whether this new medication could offer hope to people whose cancers have stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth as a tablet and attend regular study visits so doctors can monitor how you are responding and check for any side effects. The study will measure your blood levels of the medication, watch for changes in your cancer, and track how well you tolerate the treatment. The duration and frequency of visits will be explained in detail by the research team.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Collaborators
Shandong Cancer Hospital and Institute
Enrollment target
~188 participants
Started
October 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Song Jia Project manager, bachelor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.